Literature DB >> 21277012

Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells.

Jing Chen1, Lijuan Wang, Lilya V Matyunina, Christopher G Hill, John F McDonald.   

Abstract

OBJECTIVE: Ovarian cancer (OC) is the most lethal of all gynecological malignancies primarily due to the sloughing-off of highly metastatic cells from primary tumors and their subsequent spread throughout the peritoneal cavity. Since the epithelial-to-mesenchymal transition (EMT) of OC cells located at the periphery of primary tumors is essential to this process, molecular interventions that can block EMT are of potential clinical significance. Members of the miR200 family of microRNAs have been implicated in EMT in other cancers. Our purpose was to determine if miR200 family microRNAs may be involved in EMT in OC and of potential therapeutic value in reducing OC metastasis.
METHODS: Gene expression profiles of two OC cell lines with different metastatic potentials were monitored using qRT-PCR (quantitative reverse transcription polymerase chain reaction). The effect of over-expression of a miR-200 family microRNA (miR-429) in metastatic OC cells was monitored on molecular (qRT-PCR and microarray) and functional (morphology, migration, invasiveness and anchorage independence assays) levels.
RESULTS: Molecular profiling of two OC cell lines with differing metastatic potentials identified significant differences in previously established epithelial and mesenchymal cell biomarkers including E-cadherin, ZEB1, ZEB2, miR-205 and miR-200 family microRNAs. Ectopic overexpression of miR-429, a member of the miR-200 family of microRNAs, in mesenchymal-like OC cells resulted in reversal of the mesenchymal phenotype (mesenchymal-epithelial transition, MET).
CONCLUSIONS: Our results indicate that miR-429 may not only be a useful biomarker of EMT in ovarian cancer, but also of potential therapeutic value in abating OC metastasis.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21277012     DOI: 10.1016/j.ygyno.2010.12.339

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  63 in total

1.  miR-429 inhibits glioma invasion through BMK1 suppression.

Authors:  Weiyi Chen; Baogang Zhang; Wenjun Guo; Linlin Gao; Lihong Shi; Hongli Li; Shijun Lu; Yuqing Liu; Xiaolong Li
Journal:  J Neurooncol       Date:  2015-08-14       Impact factor: 4.130

2.  KLF5 activates microRNA 200 transcription to maintain epithelial characteristics and prevent induced epithelial-mesenchymal transition in epithelial cells.

Authors:  Baotong Zhang; Zhiqian Zhang; Siyuan Xia; Changsheng Xing; Xinpei Ci; Xin Li; Ranran Zhao; Sha Tian; Gui Ma; Zhengmao Zhu; Liya Fu; Jin-Tang Dong
Journal:  Mol Cell Biol       Date:  2013-10-14       Impact factor: 4.272

3.  miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin.

Authors:  X Zhu; H Shen; X Yin; L Long; C Xie; Y Liu; L Hui; X Lin; Y Fang; Y Cao; Y Xu; M Li; W Xu; Y Li
Journal:  Oncogene       Date:  2015-04-13       Impact factor: 9.867

4.  MiR-429 regulates gastric cancer cell invasiveness through ZEB proteins.

Authors:  Wei Liu; Jie An; Kang Li; Huichi Hou
Journal:  Tumour Biol       Date:  2015-10-15

5.  MicroRNAs As Biomarkers For Clinical Features Of Lung Cancer.

Authors:  Roland Hubaux; Daiana D Becker-Santos; Katey S S Enfield; Stephen Lam; Wan L Lam; Victor D Martinez
Journal:  Metabolomics (Los Angel)       Date:  2012-03-21

6.  Silencing the double-stranded RNA binding protein DGCR8 inhibits ovarian cancer cell proliferation, migration, and invasion.

Authors:  Yuqi Guo; Peng Tian; Chuanhe Yang; Zhibing Liang; Min Li; Michelle Sims; Lu Lu; Zhan Zhang; Hongwei Li; Lawrence M Pfeffer; Junming Yue
Journal:  Pharm Res       Date:  2015-03       Impact factor: 4.200

7.  Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer.

Authors:  Lyndsay V Rhodes; Syreeta L Tilghman; Stephen M Boue; Shuchun Wang; Hafez Khalili; Shannon E Muir; Melyssa R Bratton; Qiang Zhang; Guangdi Wang; Matthew E Burow; Bridgette M Collins-Burow
Journal:  Oncol Lett       Date:  2011-10-24       Impact factor: 2.967

8.  MicroRNAs and cancer: Key paradigms in molecular therapy.

Authors:  Weige Tan; Bodu Liu; Shaohua Qu; Gehao Liang; Wei Luo; Chang Gong
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

Review 9.  Learning the molecular mechanisms of the reprogramming factors: let's start from microRNAs.

Authors:  Chao-Shun Yang; Tariq M Rana
Journal:  Mol Biosyst       Date:  2012-10-05

10.  miR-429 promotes the proliferation of non-small cell lung cancer cells via targeting DLC-1.

Authors:  Peng Xiao; Wenliang Liu; Hui Zhou
Journal:  Oncol Lett       Date:  2016-07-22       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.